Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001104659-26-019168
Filing Date
2026-02-24
Accepted
2026-02-24 16:39:48
Documents
109
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K knsa-20251231x10k.htm   iXBRL 10-K 3708207
2 EX-10.26 knsa-20251231xex10d26.htm EX-10.26 70129
3 EX-10.47 knsa-20251231xex10d47.htm EX-10.47 30940
4 EX-21.1 knsa-20251231xex21d1.htm EX-21.1 7419
5 EX-23.1 knsa-20251231xex23d1.htm EX-23.1 1973
6 EX-31.1 knsa-20251231xex31d1.htm EX-31.1 14164
7 EX-31.2 knsa-20251231xex31d2.htm EX-31.2 14107
8 EX-32.1 knsa-20251231xex32d1.htm EX-32.1 7640
9 EX-32.2 knsa-20251231xex32d2.htm EX-32.2 7554
10 GRAPHIC knsa-20251231x10k006.jpg GRAPHIC 62646
11 GRAPHIC knsa-20251231x10k008.jpg GRAPHIC 48964
12 GRAPHIC knsa-20251231x10k009.jpg GRAPHIC 91770
13 GRAPHIC knsa-20251231x10k010.jpg GRAPHIC 94553
14 GRAPHIC knsa-20251231x10k011.jpg GRAPHIC 64941
  Complete submission text file 0001104659-26-019168.txt   15891498

Data Files

Seq Description Document Type Size
15 EX-101.SCH knsa-20251231.xsd EX-101.SCH 82609
16 EX-101.CAL knsa-20251231_cal.xml EX-101.CAL 93569
17 EX-101.DEF knsa-20251231_def.xml EX-101.DEF 404418
18 EX-101.LAB knsa-20251231_lab.xml EX-101.LAB 755218
19 EX-101.PRE knsa-20251231_pre.xml EX-101.PRE 613552
112 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20251231x10k_htm.xml XML 2963316
Mailing Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ
Business Address 105 PICCADILLY, SECOND FLOOR LONDON United Kingdom W1J 7NJ 7814319100
Kiniksa Pharmaceuticals International, plc (Filer) CIK: 0001730430 (see all company filings)

EIN.: 981795578 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-38492 | Film No.: 26672380
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)